{"id":57799,"date":"2024-11-23T05:21:01","date_gmt":"2024-11-23T05:21:01","guid":{"rendered":"https:\/?p=57799"},"modified":"2024-11-23T05:21:01","modified_gmt":"2024-11-23T05:21:01","slug":"autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/","title":{"rendered":"Autolus Therapeutics: Goldman Sachs &#8220;Top Pick&#8221;, Forecasts Almost 3x Upside"},"content":{"rendered":"<div class=\"flex-1 overflow-hidden\">\n<div class=\"h-full\">\n<div class=\"react-scroll-to-bottom--css-dzwts-79elbk h-full\">\n<div class=\"react-scroll-to-bottom--css-dzwts-1n7m0yu\">\n<div class=\"flex flex-col text-sm md:pb-9\">\n<article class=\"w-full scroll-mb-[var(--thread-trailing-height,150px)] text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]\" dir=\"auto\" data-testid=\"conversation-turn-5\" data-scroll-anchor=\"true\">\n<div class=\"m-auto text-base py-[18px] px-3 md:px-4 w-full md:px-5 lg:px-4 xl:px-5\">\n<div class=\"mx-auto flex flex-1 gap-4 text-base md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\">\n<div class=\"group\/conversation-turn relative flex w-full min-w-0 flex-col agent-turn\">\n<div class=\"flex-col gap-1 md:gap-3\">\n<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"df279fb1-be7f-4f76-97f6-4fc5dae3cb3f\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<h3>Autolus Therapeutics Ltd. (AUTL)<\/h3>\n<p>Goldman Sachs <a href=\"https:\/\/www.stocktargetadvisor.com\/Analyst-Ranking\/Goldman-Sachs-&amp;-Co.\">(Analyst Rank#10)<\/a> has identified <strong>Autolus Therapeutics Ltd<\/strong> as a &#8220;Top Pick&#8221; in the biotechnology sector, projecting a potential upside of nearly 3x its current stock price. This bullish outlook reflects confidence in the company\u2019s innovative pipeline, strong positioning within the cell therapy space, and potential catalysts that could drive significant value in the near to medium term.<\/p>\n<ul>\n<li><strong>Biotech Pipeline<\/strong>: Autolus focuses on T-cell therapies for cancer, a highly promising and competitive field. Their clinical programs, particularly for hematologic cancers, could be pivotal in achieving breakthrough status and garnering market attention.<\/li>\n<li><strong>Valuation Opportunity<\/strong>: At its current price, the stock may be perceived as undervalued relative to its long-term growth prospects, making it an attractive investment for risk-tolerant investors.<\/li>\n<\/ul>\n<hr \/>\n<p><strong>Stock Forecast and Analyst Sentiment<\/strong><\/p>\n<ul>\n<li><strong>Analyst Target Price<\/strong>: The average 12-month price target from four analysts is <strong>USD 10.10<\/strong>, implying a potential upside of over <strong>256%<\/strong> from the last closing price of <strong>USD 2.84<\/strong>. This reflects high expectations for the company\u2019s clinical success and commercialization prospects.<\/li>\n<li><strong>Analyst Rating<\/strong>: Autolus has an average rating of <strong>Strong Buy<\/strong>, indicating broad optimism among analysts regarding its growth trajectory and the potential of its therapies to disrupt the oncology space.<\/li>\n<li><strong>Stock Target Advisor Rating<\/strong>: Contrastingly, Stock Target Advisor\u2019s proprietary analysis rates the stock as <strong>Bearish<\/strong>, based on <strong>2 positive signals<\/strong> and <strong>6 negative signals<\/strong>. This divergence underscores the inherent risks in biotech investments, such as clinical trial outcomes, regulatory challenges, and funding requirements.<\/li>\n<\/ul>\n<hr \/>\n<p><strong>Recent Stock Performance<\/strong><\/p>\n<ul>\n<li><strong>Last Closing Price<\/strong>: At <strong>USD 2.84<\/strong>, the stock is trading significantly below the consensus target, which may present a buying opportunity if Goldman Sachs\u2019 and other analysts\u2019 forecasts materialize.<\/li>\n<li><strong>Price Changes<\/strong>:\n<ul>\n<li><strong>Past Week<\/strong>: Declined by <strong>-5.65%<\/strong>, suggesting near-term market pessimism or broader sector weakness.<\/li>\n<li><strong>Past Month<\/strong>: Dropped by <strong>-37.17%<\/strong>, which could reflect investor concerns over funding, clinical trial delays, or general market sentiment toward speculative biotech stocks.<\/li>\n<li><strong>Past Year<\/strong>: Fell by <strong>-36.61%<\/strong>, indicating persistent challenges. However, this also emphasizes the potential for a turnaround if key milestones are achieved.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<hr \/>\n<p><strong>Key Considerations<\/strong><\/p>\n<ul>\n<li><strong>Catalysts<\/strong>: Upcoming clinical trial results, regulatory approvals, or strategic partnerships could serve as significant drivers for the stock. Positive developments in these areas would likely validate Goldman Sachs\u2019 bullish stance.<\/li>\n<li><strong>Risks<\/strong>: As with any biotechnology company, Autolus faces uncertainties around trial outcomes, high R&amp;D costs, and market competition. These factors could lead to further volatility in its stock price.<\/li>\n<\/ul>\n<h3>Outlook<\/h3>\n<p>Autolus Therapeutics Ltd presents a high-risk, high-reward scenario. While Goldman Sachs\u2019 endorsement and the substantial upside potential are encouraging, investors must weigh this against the bearish technical indicators and recent underperformance. For those with a strong appetite for risk, this could be an opportunity to invest in a potentially transformative player in the oncology space.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\">\n<div class=\"items-center justify-start rounded-xl p-1 flex\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"md:pt-0 dark:border-white\/20 md:border-transparent md:dark:border-transparent w-full\">\n<div>\n<div class=\"relative w-full px-2 py-2 text-center text-xs text-token-text-secondary empty:hidden md:px-[60px]\">\n<div class=\"min-h-4\">\n<div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Autolus Therapeutics Ltd. (AUTL) Goldman Sachs (Analyst Rank#10) has identified Autolus Therapeutics Ltd as a &#8220;Top Pick&#8221; in the biotechnology sector, projecting a potential upside&#8230;<\/p>\n","protected":false},"author":3,"featured_media":57801,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-57799","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-blog","post_format-post-format-image"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Autolus Therapeutics: Goldman Sachs &quot;Top Pick&quot;, Forecasts Almost 3x Upside | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Therapeutics: Goldman Sachs &quot;Top Pick&quot;, Forecasts Almost 3x Upside\" \/>\n<meta property=\"og:description\" content=\"Autolus Therapeutics Ltd. (AUTL) Goldman Sachs (Analyst Rank#10) has identified Autolus Therapeutics Ltd as a &#8220;Top Pick&#8221; in the biotechnology sector, projecting a potential upside...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-23T05:21:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/autolus_ltd__logo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"Autolus Therapeutics: Goldman Sachs &#8220;Top Pick&#8221;, Forecasts Almost 3x Upside\",\"datePublished\":\"2024-11-23T05:21:01+00:00\",\"dateModified\":\"2024-11-23T05:21:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/\"},\"wordCount\":460,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/\",\"name\":\"Autolus Therapeutics: Goldman Sachs \\\"Top Pick\\\", Forecasts Almost 3x Upside | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-11-23T05:21:01+00:00\",\"dateModified\":\"2024-11-23T05:21:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autolus Therapeutics: Goldman Sachs &#8220;Top Pick&#8221;, Forecasts Almost 3x Upside\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Autolus Therapeutics: Goldman Sachs \"Top Pick\", Forecasts Almost 3x Upside | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Therapeutics: Goldman Sachs \"Top Pick\", Forecasts Almost 3x Upside","og_description":"Autolus Therapeutics Ltd. (AUTL) Goldman Sachs (Analyst Rank#10) has identified Autolus Therapeutics Ltd as a &#8220;Top Pick&#8221; in the biotechnology sector, projecting a potential upside...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-11-23T05:21:01+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/autolus_ltd__logo.jpeg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"Autolus Therapeutics: Goldman Sachs &#8220;Top Pick&#8221;, Forecasts Almost 3x Upside","datePublished":"2024-11-23T05:21:01+00:00","dateModified":"2024-11-23T05:21:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/"},"wordCount":460,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/","name":"Autolus Therapeutics: Goldman Sachs \"Top Pick\", Forecasts Almost 3x Upside | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-11-23T05:21:01+00:00","dateModified":"2024-11-23T05:21:01+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/autolus-therapeutics-goldman-sachs-top-pick-forecasts-almost-3x-upside\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Autolus Therapeutics: Goldman Sachs &#8220;Top Pick&#8221;, Forecasts Almost 3x Upside"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/57799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=57799"}],"version-history":[{"count":2,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/57799\/revisions"}],"predecessor-version":[{"id":57803,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/57799\/revisions\/57803"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/57801"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=57799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=57799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=57799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}